文献速递肺栓塞与肺血管病

BACS评分:急性肺栓塞溶栓相关大出血的临床预测规则

Derivation and validation of a clinical prediction rule for thrombolysis-associated major bleeding in patients with acute pulmonary embolism: the BACS score.
PubMed 文献 · Eur Respir J · 2020-12-03

基于RIETE注册研究中1172例接受全身溶栓的急性肺栓塞患者,构建并外部验证(COMMAND VTE注册研究)了预测30天大出血的BACS评分。评分包含近期大出血(3分)、年龄>75岁(1分)、活动性癌症(1分)和晕厥(1分)。低危组(0分)30天大出血率为2.9%(95%CI 1.6-4.9%),高危组(>3分)为44%(95%CI 14-79%)。

要点

  • BACS评分包含近期大出血、年龄>75岁、活动性癌症和晕厥四个预测因子。
  • 低危组(0分)30天大出血率为2.9%,高危组(>3分)为44%。
  • BACS评分可能有助于指导肺栓塞溶栓治疗的选择。

核心结论

  • BACS评分是预测接受全身溶栓的肺栓塞患者大出血风险的简便工具。

研究设计与样本

  • 研究基于RIETE注册研究中连续接受全身溶栓的急性肺栓塞患者,使用多变量logistic回归分析构建风险评分,并在COMMAND VTE注册研究中进行外部验证。
  • 推导队列包含1172例患者,验证队列包含290例患者。

主要发现

  • 多变量logistic回归识别出四个大出血预测因子:近期大出血(3分)、年龄>75岁(1分)、活动性癌症(1分)和晕厥(1分)。
  • 在RIETE队列中,446例(38%)被BACS评分归类为低危(0分),该组30天大出血率为2.9%(95%CI 1.6-4.9%);高危组(>3分)为44%(95%CI 14-79%)。
  • 在验证队列中,51%(149/290)被归类为低危,该组30天大出血率为1.3%。
  • 在RIETE中,Kuijer和RIETE低危分层的30天大出血事件率分别为5.3%和4.4%。

关键数值与推荐

  • BACS评分低危定义为0分(无任何变量),高危定义为>3分。

临床怎么用

  • BACS评分可用于接受全身溶栓的急性肺栓塞患者的大出血风险分层,辅助治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Improved prediction of the risk of major bleeding in patients with acute pulmonary embolism (PE) receiving systemic thrombolysis is crucial to guide the choice of therapy. METHODS: The study included consecutive patients with acute PE who received systemic thrombolysis in the RIETE registry. We used multivariable logistic regression analysis to create a risk score to predict 30-day major bleeding episodes. We externally validated the risk score in patients from the COMMAND VTE registry. In addition, we compared the newly created risk score against the Kuijer and RIETE scores. RESULTS: Multivariable logistic regression identified four predictors for major bleeding: recent major bleeding (3 points), age >75 years (1 point), active cancer (1 point) and syncope (1 point) (BACS). Among 1172 patients receiving thrombolytic therapy in RIETE, 446 (38%) were classified as having low risk (none of the variables present, 0 points) of major bleeding according to the BACS score, and the overall 30-day major bleeding rate of this group was 2.9% (95% CI 1.6-4.9%), compared with 44% (95% CI 14-79%) in the high-risk group (>3 points). In the validation cohort, 51% (149 out of 290) of patients were classified as having low risk, and the overall 30-day major bleeding rate of this group was 1.3%. In RIETE, the 30-day major bleeding event rates in the Kuijer and RIETE low-risk strata were 5.3% and 4.4%, respectively. CONCLUSIONS: The BACS score is an easily applicable aid for prediction of the risk of major bleeding in the population of PE patients who receive systemic thrombolysis.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Jara-Palomares L, Jiménez D, Bikdeli B, et al. Derivation and validation of a clinical prediction rule for thrombolysis-associated major bleeding in patients with acute pulmonary embolism: the BACS score. Eur Respir J. 2020. PMID: 32703772. doi:10.1183/13993003.02336-2020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。